Seer, Inc.

NasdaqGS SEER

Seer, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -1.63

Seer, Inc. Price to Earnings Ratio (P/E) is -1.63 on January 14, 2025, a -24.17% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Seer, Inc. 52-week high Price to Earnings Ratio (P/E) is -1.16 on February 23, 2024, which is 29.13% above the current Price to Earnings Ratio (P/E).
Seer, Inc. 52-week low Price to Earnings Ratio (P/E) is -1.82 on December 10, 2024, which is -11.35% below the current Price to Earnings Ratio (P/E).
Seer, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -1.43.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: SEER

Seer, Inc.

CEO	Dr. Omid C. Farokhzad M.D., Ph.D.
IPO Date	Dec. 4, 2020
Location	United States
Headquarters	3800 Bridge Parkway
Employees	147
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends

Past 5 years